Zacks Research Upgrades Telomir Pharmaceuticals (NASDAQ:TELO) to “Hold”

Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by research analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

TELO has been the topic of a number of other reports. Wall Street Zen upgraded shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Thursday, January 22nd. Finally, Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

NASDAQ:TELO opened at $1.32 on Wednesday. The company has a market cap of $45.38 million, a PE ratio of -4.00 and a beta of -0.66. Telomir Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $4.81. The stock has a 50-day simple moving average of $1.26 and a 200 day simple moving average of $1.36.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. On average, research analysts predict that Telomir Pharmaceuticals will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC boosted its holdings in shares of Telomir Pharmaceuticals by 64.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock valued at $32,000 after buying an additional 9,000 shares during the last quarter. Bank of America Corp DE lifted its stake in Telomir Pharmaceuticals by 283.9% in the fourth quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after acquiring an additional 10,880 shares during the last quarter. Praetorian Wealth Management Inc. bought a new position in shares of Telomir Pharmaceuticals in the 3rd quarter valued at about $28,000. Qube Research & Technologies Ltd acquired a new position in shares of Telomir Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Geode Capital Management LLC raised its holdings in shares of Telomir Pharmaceuticals by 14.0% in the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares during the period.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.